RC
LYEL icon

Rangeley Capital’s Lyell Immunopharma LYEL Stock Holding History

Rangeley Capital’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$162K – 144
2025
Q3 		$162K Buy
+10,000
New +$114K 0.14% 100
2025
Q2 		– Sell
-500
Closed -$5.38K – 95
2025
Q1 		$5.38K Buy
+500
New +$6.13K 0.01% 77

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
MCL
MWG Caph Ltd Charlestown $72.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Rangeley Capital's LYEL Position: Q4 2025 in Review

Rangeley Capital sold out of Lyell Immunopharma (LYEL) in Q4 2025, closing a stake of 10,000 shares — an estimated $162K sold.

Rangeley Capital first reported a position in LYEL in Q1 2025 and held it in 2 quarters. The position peaked at $162K in Q3 2025. 68 funds tracked by Wall St. Rank hold LYEL as of Q4 2025.

  • Rangeley Capital reported no remaining Lyell Immunopharma position as of Q4 2025 after selling out during the quarter.
  • Rangeley Capital sold 10,000 Lyell Immunopharma shares in Q4 2025, an estimated $162K.
  • Rangeley Capital first reported a position in Lyell Immunopharma in Q1 2025 and held it in 2 quarters.
  • Rangeley Capital's Lyell Immunopharma position peaked at $162K in Q3 2025.
  • 68 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2025.

Based on Rangeley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.